Kanada - Inggris - Health Canada

jubilant generics limited - deferasirox - tablet - 360mg - deferasirox 360mg

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 125mg;  ;   - dispersible tablet - 125 mg - active: deferasirox 125mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 250mg;  ;   - dispersible tablet - 250 mg - active: deferasirox 250mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 500mg;  ;   - dispersible tablet - 500 mg - active: deferasirox 500mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.